Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease.
暂无分享,去创建一个
J. Brandt | R. Lewis | G. Harris | A. Codori | J Brandt | G J Harris | R F Lewis | A. Bedi | A M Codori | E Schmidt | A Bedi | E. Schmidt | Jason Brandt | Gordon J. Harris | Eike Schmidt | Asheesh Bedi
[1] G. Dobben,et al. Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy , 1978, Neurology.
[2] H. Herzog,et al. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease , 1989, Psychiatry Research.
[3] S. Folstein,et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.
[4] C. Markham,et al. Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.
[5] S. Folstein. Huntington's disease : a disorder of families , 1989 .
[6] ACMG/ASHG statement. Laboratory guidelines for Huntington disease genetic testing. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. , 1998, American journal of human genetics.
[7] M. Hayden,et al. Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.
[8] R J Leigh,et al. The measurement of abnormal movement: methods developed for Huntington's disease. , 1983, Neurobehavioral toxicology and teratology.
[9] I. Shoulson,et al. Clinical‐pathologic correlation in Huntington's disease , 1989, Neurology.
[10] R. Hichwa,et al. Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function , 1988, Annals of neurology.
[11] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[12] O. Paulson,et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[13] N. Butters,et al. Computed tomographic, neurologic, and neuropsychological correlates of Huntington's disease. , 1983, The International journal of neuroscience.
[14] H Toyama,et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] G D Pearlson,et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. , 1996, Archives of neurology.
[16] S. Folstein,et al. Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.
[17] J C Mazziotta,et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.
[18] P F Sharp,et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] W. Martin,et al. Cortical glucose metabolism in Huntington's disease , 1992, Neurology.
[20] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.
[21] L. Carrasco,et al. ATROPHY OF CORPUS STRIATUM IN NORMAL MALE AT RISK OF HUNTINGTON'S CHOREA , 1986, The Lancet.
[22] Robin L. Bennett,et al. Laboratory Guidelines for Huntington Disease Genetic Testing , 1998 .
[23] J. Mazziotta,et al. Studies in persons at risk for Huntington's disease. , 1987, The New England journal of medicine.
[24] S. Folstein,et al. Trial of d-α-tocopherol in Huntington's disease , 1995 .
[25] G Pearlson,et al. Bicaudate ratio as a measure of caudate volume on MR images. , 1991, AJNR. American journal of neuroradiology.
[26] M. Hayden,et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease , 1987, Neurology.
[27] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[28] S. Folstein,et al. Neuropsychological and neuroradiological correlates in Huntington's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[29] R. Roos,et al. Neuronal distribution in the putamen in Huntington's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.
[30] H. Herzog,et al. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of huntington's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[31] Scott T. Grafton,et al. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease. , 1992, Archives of general psychiatry.
[32] Jack L. Lancaster,et al. A modality‐independent approach to spatial normalization of tomographic images of the human brain , 1995 .
[33] G D Pearlson,et al. Brain atrophy in Huntington's disease. A CT-scan study. , 1989, Neuroradiology.
[34] G. Pearlson,et al. MRI-guided region of interest placement on emission computed tomograms , 1993, Psychiatry Research: Neuroimaging.
[35] J. Mazziotta,et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.
[36] G. E. Alexander,et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.
[37] Terry L. Jernigan,et al. Cerebral structure on MRI, part II: Specific changes in Alzheimer's and Huntington's diseases , 1991, Biological Psychiatry.
[38] Cerebral blood flow velocity decreases during cognitive stimulation in Huntington's disease , 1998, Neurology.
[39] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[40] A. Franks. Function and dysfunction in the basal ganglia , 1990 .
[41] Scott T. Grafton,et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.
[42] R. Hichwa,et al. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.
[43] C. Nahmias,et al. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease , 1984, Journal of the Neurological Sciences.
[44] R. Hichwa,et al. Normal caudate glucose metabolism in persons at risk for Huntington??s disease , 1987 .
[45] G. Pearlson,et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. , 1996, Archives of neurology.
[46] H. Herzog,et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.